EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Rewiring PD-1/PD-L1 combination therapy via glyco-immune targeting of galectins: Toward clinical translation

Xiangyu Huang, Si Zhang, Jiale Li, She Chen

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025

DOI: 10.1016/j.bbcan.2025.189496 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025. Verfasst von Xiangyu Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, …. Hauptthemen laut MEDLINE: Galectins, B7-H1 Antigen, Neoplasms, Programmed Cell Death 1 Receptor. Die Arbeit nennt 79 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in PD-1/PD-L1 combination therapies, clinical benefits remain limited and toxicity is significant. Galectins, a family of β-galactoside-binding lectins, have emerged as mechanistically distinct, multimodal targets with the potential to address these limitations. By modulating glycan-protein networks in the tumor microenvironment, galectin inhibition alleviates T cell exclusion, immune exhaustion, immunosuppressive cell activation, and steric blockade of PD-(L)1 antibodies. Several galectin inhibitors (e.g., GR-MD-02, GB1211, LYT-200) are under clinical evaluation. Early trials showing encouraging efficacy-toxicity profiles and some combinations received FDA Fast Track designations. This review summarizes mechanistic and clinical advances and highlights their translational implications for galectin-targeted combination therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GalectinsB7-H1 AntigenNeoplasmsProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsHumansTumor MicroenvironmentAnimalsMolecular Targeted Therapy

Stichwörter der Autor:innen

GalectinGalectin inhibitorsGalectin-targeted combination therapyPD-1/PD-L1Translational immunotherapy

Substanzen

GalectinsB7-H1 AntigenProgrammed Cell Death 1 ReceptorCD274 protein, humanPDCD1 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 130 Dong'an Road, Xuhui District, Shanghai 200032, China.
  • NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 130 Dong'an Road, Xuhui District, Shanghai 200032, China. Electronic a…

Förderung

  • National Natural Science Foundation of China
  • Shanghai Municipal Natural Science Foundation

Zitieren

APA

Huang, X., Zhang, S., Li, J., & Chen, S. (2025). Rewiring PD-1/PD-L1 combination therapy via glyco-immune targeting of galectins: Toward clinical translation. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189496

Vancouver

Huang X, Zhang S, Li J, Chen S. Rewiring PD-1/PD-L1 combination therapy via glyco-immune targeting of galectins: Toward clinical translation. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025. doi:10.1016/j.bbcan.2025.189496

BibTeX
@article{Huang2025,
  author = {Huang, Xiangyu and Zhang, Si and Li, Jiale and Chen, She},
  title = {Rewiring PD-1/PD-L1 combination therapy via glyco-immune targeting of galectins: Toward clinical translation},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2025},
  doi = {10.1016/j.bbcan.2025.189496}
}
Kostenlos starten →